stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) Shares outstanding
AbCellera Biologics Inc.'s shares outstanding at the end of fiscal 2025 was $298.7M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $305.6M. Over the past ten years it has ranged from $151.3M (fiscal 2019) to $318.3M (fiscal 2021); the current reading is higher than 75% of that period. AbCellera Biologics Inc. ranks 22nd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $298.7M | 1.49% |
| FY2024 | $294.3M | 1.79% |
| FY2023 | $289.2M | (8.15%) |
| FY2022 | $314.8M | (1.09%) |
| FY2021 | $318.3M | 20.96% |
| FY2020 | $263.1M | 73.88% |
| FY2019 | $151.3M | (11.68%) |
| FY2018 | $171.3M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $305.6M | 0.82% |
| Mar 2026 | $303.1M | 1.46% |
| Dec 2025 | $298.7M | (0.06%) |
| Sep 2025 | $298.9M | 0.12% |
| 22 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IOVA Iovance Biotherapeutics, Inc. compare | $450.2M |
| ABCL AbCellera Biologics Inc. | $305.6M |
| RLAY Relay Therapeutics, Inc. compare | $202.8M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $175.5M |
| TNGX Tango Therapeutics, Inc. compare | $149.9M |
| ARQT Arcutis Biotherapeutics, Inc. compare | $135.9M |
| EWTX Edgewise Therapeutics, Inc. compare | $107.7M |
| XENE Xenon Pharmaceuticals Inc. compare | $99.6M |
| PBLS Parabilis Medicines, Inc. compare | $28.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ABCL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement